is tirzepatide a glp 1 agonist Bumps and humps in the success of as the first GLP1 and GIP receptor Unveiling Tirzepatide's Therapeutic Spectrum: A

Kadouh H, Chedid V, Halawi H, et al

In the AOM market, the best-in-class medication is likely to be determined by not only clinical efficacy in terms of weight reduction, but also in terms of weight maintenance, impact on ORCs and mode of administration

[DOI] [PubMed] [Google Scholar] 294.Edfalk S., Steneberg P., Edlund H

They are recognized as effective therapies for glycemic control, with additional benefits in weight reduction and cardiovascular risk

Limited insurance coverage and affordability issues create barriers to widespread patient access, particularly in lower-income populations and countries with stringent pricing regulations